Unknown

Dataset Information

Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review.


ABSTRACT: Cystic fibrosis (CF) is a rare, progressive, multi-organ genetic disease. Ivacaftor, a small-molecule CF transmembrane conductance regulator modulator, was the first medication to treat the underlying cause of CF. Since its approval, real-world clinical experience on the use of ivacaftor has been documented in large registries and smaller studies. Here, we systematically review data from real-world observational studies of ivacaftor treatment in people with CF (pwCF). Searches of MEDLINE and Embase identified 368 publications reporting real-world studies that enrolled six or more pwCF treated with ivacaftor published between January 2012 and September 2019. Overall, 75 publications providing data from 57 unique studies met inclusion criteria and were reviewed. Studies reporting within-grou

SUBMITTER: Duckers J 

PROVIDER: S-EPMC8038673 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature